Eyedetec Medical specializes in medical devices for the treatment of dry eye and meibomian gland dysfunction.
— Barry J. Linder, MD, MS, President and CEO of Eyedetec Medical
DANVILLE, CALIFORNIA, USA, April 18, 2022 /EINPresswire.com/ — Eyedetec Medical, Inc., an innovative developer of treatments for dry eye caused by meibomian gland dysfunction, is pleased to have finished among the six top companies in Eyecelerator’s newest eye treatment technology competition, “The Winning Pitch Challenge – ASCRS 2022”.
Eyedetec Medical’s latest invention for the treatment of Meibomian Gland Dysfunction (MGD) received an honorable mention from the contest judges.
“We were amazed by the quality and diversity of innovative ideas submitted from around the world,” Eyecelerator said when announcing the winners. “It was an impressive group of submissions. The judges spent a considerable amount of time reviewing the pitch decks” before choosing the three finalists and three honorable mention winners.
The device that earned the honorable mention Eyecelerator will use a patented mechanism of action to mobilize lipids inside the glands of the eyelids, thereby stabilizing and restoring the tear film naturally.
Barry J. Linder, MD, MS, President and CEO of Eyedetec Medical, added the following statement:
“We are thrilled to have received this endorsement from the judges that our latest innovation in dry eye treatment technology has great potential to improve outcomes and quality of life for patients suffering from this condition.”
As many as 30 million Americans suffer from some form of dry eye, with meibomian gland dysfunction implicated in nearly 85% of all cases. Dry eye is incurable and chronic. If left untreated, it can cause serious permanent damage to the eye while negatively impacting quality of life. However, continued treatment can control symptoms and prevent progression of dry eye disease.
“Given the chronic and incurable nature of dry eye disease, continued innovation around effective treatment is essential,” Linder said. “Patients also need to be educated so that they share their symptoms with their eye care professional at each visit. Too many patients consider dry eye symptoms such as gritty, gummy and, ironically, excessive tearing to be normal symptoms of eye strain.
Linder looks forward to meeting investors and other entrepreneurs at the Eyecelerator meeting in Washington DC on April 21, during the ASCRS annual convention.
About Eyedetec Medical, Inc.
Eyedetec Medical specializes in medical devices for the treatment of dry eye and meibomian gland dysfunction. Eyedetec’s growth is fueled by a passion for providing product solutions that meet patient needs in a practical, user-friendly, efficient, comfortable and affordable way.
Eyedetec’s first product, the EyeGiene® Insta-Warmth System™, is a clinically proven medical device indicated for the treatment of dry eye.
Eyedetec is currently developing the next generation therapy to treat dry eye that will be initiated in medical offices and then only continued at the patient’s home. . Eyedetec’s overriding goal remains to provide patients with lasting relief from the discomforts of dry eye.
Eyecelerator is a partnership between the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology to connect entrepreneurs, investors, corporations, and ophthalmologists to accelerate ophthalmic innovation and improve patient outcomes. The goal is to drive innovation to help patients and advance the profession by helping physicians engage with an ecosystem of like-minded people.
For more information, visit eyecelerator.com.
write to us here